Jazz Pharmaceuticals Announces CEO Succession Plan

Jazz Pharmaceuticals plc Ireland

for more information.

Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the Company's 2024 total revenue guidance and the Company's expectations related thereto; and the Company's expectations with respect to the timing and outcome of the search process for the Company's next chief executive officer. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: identifying and attracting a qualified candidate to serve as the Company's next chief executive officer on the Company's anticipated timing or at all; maintaining or increasing sales of, and revenue from, Xywav, Rylaze and Epidiolex/Epidyolex and other marketed products; the introduction of new products into the U.S. market that compete with, or otherwise disrupt the market for the Company's products and product candidates; the Company's ability to achieve targeted or expected future financial performance and results, including the Company's 2024 total revenue guidance; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in the Company's Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as supplemented by the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and future filings and reports by the Company. Other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

Contacts:
Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
[e-mail]
Ireland [phone]
U.S. [phone]

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[e-mail]
Ireland [phone]
U.S. [phone]

Logo - https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-announces-ceo-succession-plan-302332986.html

@ prnewswire.co.uk